
Reset all filters
01 3Oxbryta
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2022 Revenue in Millions : 73
2021 Revenue in Millions : 0
Growth (%) : 100
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2023 Revenue in Millions : 328
2022 Revenue in Millions : 73
Growth (%) : 349
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2024 Revenue in Millions : 201
2023 Revenue in Millions : 328
Growth (%) : -39